Novo Nordisk Launches Wegovy Oral Tablet in UAE as First International Market Outside US

Novo Nordisk's decision to debut the oral formulation of Wegovy (semaglutide) in the UAE before any other international market signals a deliberate regulatory and commercial sequencing that supply chain and QA teams in the region will need to track closely. The rollout marks the first time the tablet form of the GLP-1 receptor agonist has been approved and distributed outside the United States, placing UAE-based manufacturing and distribution partners under immediate compliance scrutiny.

For regulatory affairs leads, the UAE approval pathway represents a reference case for how Gulf Cooperation Council markets may handle accelerated reviews of already-approved novel oral formulations. The oral semaglutide tablet carries distinct CMC and stability requirements compared to the subcutaneous injection, including absorption enhancer co-formulation with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), which introduces specific dissolution testing and packaging integrity considerations under ICH Q1 and regional shelf-life expectations.

Distribution infrastructure for the UAE launch will need to meet cold-chain and humidity-control standards consistent with the country's climatic zone designation, a factor that QA directors managing third-party logistics agreements should verify against existing qualification data. Any gap between the validated storage conditions established for the US market and UAE ambient conditions would require bridging studies before local batch release.

The sequencing of this launch ahead of European and other established markets may reflect the UAE's comparatively streamlined approval timeline through the Ministry of Health and Prevention (MoHAP), rather than a manufacturing or supply readiness advantage. Regulatory leads monitoring semaglutide oral filings in the EU and UK should treat the UAE data package as an early indicator of the dossier structure Novo Nordisk is advancing internationally.

Novo Nordisk has not publicly disclosed the local manufacturing or fill-finish partner for the UAE supply chain, leaving open questions about batch traceability and QP release arrangements that will become relevant as volume scales.

Source: Media4Growth via Indian Pharma Post, 3 June 2026.